Macquarie University researchers have discovered new information about how oral cancer cells may block the body's immune ...

A new study has uncovered pathways used by oral cancer to evade the immune system, potentially opening doors for improved treatments, including protein interactions that could be key to fighting ...

US FDA approves AstraZeneca’s Tagrisso for patients with unresectable, stage III EGFR-mutated lung cancer: Cambridge, UK Friday, September 27, 2024, 11:00 Hrs [IST] AstraZenecas ...

The research focused on a protein called ‘signal transducer and ... much higher in all oral cancer cell types studied ...

The research focused on a protein called 'signal transducer and ... much higher in all oral cancer cell types studied compared to normal oral cells. They also found a protein called epidermal growth ...

Pacylex was recognized as BioAlberta's 2024 Company of the Year. The award acknowledges a company that has shown significant achievement within the marketplace and Alberta's business community through ...

Analysis of ctDNA in the MARIPOSA trial showed fewer EGFR alterations and MET amplifications after Rybrevant-Lazcluze treatment than after Tagrisso.

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca’s TAGRISSO ® (osimertinib) has been approved in the US for the treatment of adult patients with unresectable, Stage III epidermal growth factor ...

Resistance to therapies in NSCLC, particularly in areas of EGFR and ALK resistance, remains a major challenge, as cancer cells find alternative survival ... which are involved in key signaling ...

Robert Burns, an analyst from H.C. Wainwright, reiterated the Buy rating on Black Diamond Therapeutics (BDTX – Research Report). The ...